Feature | August 28, 2012| Nicole Fornell, Pharm D

Use of Platelet Function Testing — Does it really aid patient management?

There is already clinical data to support use of prasugrel, ticagrelor over clopidogrel

Verifynow platelet testing clopidogrel nonresponders

A major issue with clopidogrel is that one-third of patients are nonresponders because they lack the enzymes to metabolize it. While nonresponders can be identified with testing, this adds cost. So with the introduction of the newer antiplatelet agents, which are metabolized differently, some hospitals and physicians are opting for ticagrelor or prasugrel. However, with generic versions of clopidogrel now available at a much lower cost than the newer agents, the question remains if patients should be tested  first to see if they will respond to Plavix.

Patients with 2C19 that is less active due to loss of gene copies are poor metabolizers of clopidogrel, opening patients to the possibility of a higher rate of mayocardial infacrtion (MI). There are assays for platelet function response (VerifyNow) and genetic tests to measure patient response, which could help determine if generic clopdogrel or more expensive agents should be used.

However, Malcolm R. Bell, MBBS, FRACP, FACC, Mayo Clinic, Rochester, Minn., said platelet function tests have only a modest predictive value. He said these tests do not have optimal methods defined and timing is undefined.

Most cardiologists do not use routine platelet testing because the patient is at high risk for poor clinical outcomes. This is because testing only counts for less than 20 percent of hypo responders due to variations in CYP2C19 enzymes. Bell and other experts presenting on antiplatelet response at the American College of Cardiology (ACC) 2012 said there is not enough information to base practice on the results of these tests. Part of the nonresponse issue is due to poor compliance by the patient. Guidelines state a IIb level of evidence to test for a high risk of poor clinical outcomes or to switch agents, but not for routine testing of platelet aggregation.

In an ACC 2012 cardiac pharmacology panel discussion, there was discussion of making platelet response testing a prior authorization requirement before newer, more expensive agents would be covered. But, speakers emphasized there is no data to say that a patient who has sticking platelets on clopidogrel will respond better with another agent. For now, it is not known what to do with this information. 

There is already clinical data to support use of prasugrel and ticagrelor over clopidogrel without testing. Therefore, platelet testing may be a moot point due to the increased cost.

Related Content

Intact Vascular, TOBA clinical study, one-year results, Tack Endovascular System, Journal of Vascular Surgery
News | Peripheral Arterial Disease (PAD)| August 24, 2016
Intact Vascular Inc. announced that the one-year results from its Tack Optimized Balloon Angioplasty (TOBA) clinical...
nanoparticles, blood clotting, internal bleeding, American Chemical Society study, Erin B. Lavik

Nanoparticles (green) help form clots in an injured liver. The researchers added color to the scanning electron microscopy image after it was taken. Image courtesy of Erin Lavik, Ph.D.

News | Hemostasis Management| August 24, 2016
August 24, 2016 — Whether severe trauma occurs on the battlefield or the highway, saving lives often comes down to...
Technavio report, renal denervation devices, 2015
News | Renal Denervation| August 23, 2016
August 23, 2016 — Technavio analysts forecast the global...
Jason Burdick, injectable hydrogels, heart failure, heart attack, American Chemical Society

Compared to other types of hydrogels being developed (left), a new hydrogel (right) can form crosslinks after injection into the heart, making the material stiffer and longer-lasting. Image courtesy of American Chemical Society.

News | Heart Failure| August 23, 2016
August 23, 2016 — During a heart attack, clots or narrowed arteries block blood flow, harming or killing cells within
News | Peripheral Arterial Disease (PAD)| August 22, 2016
Avinger Inc. recently announced the closing of its previously announced public offering of 9,857,800 shares of Avinger’...
DMC Heart Hospital, Detroit Medical Center, complex percutaneous intervention education course, PCI, cath lab training
News | Cath Lab| August 22, 2016
The Detroit Medical Center (DMC) Heart Hospital recently completed a Complex Percutaneous Intervention education course...
TAILOR-PCI study, antiplatelet medication, genotype, NHLBI grant
News | Antiplatelet and Anticoagulation Therapies| August 18, 2016
Researchers at the Peter Munk Cardiac Centre, Toronto, and at Mayo Clinic are leading the Tailored Antiplatelet Therapy...
Covidien, Medtronic, TurboHawk, Atherectomy system

The Medtronic TurboHawk atherectomy system. 

Feature | Atherectomy Devices| August 18, 2016 | Dave Fornell
Due to poor outcomes from percutaneous transluminal angioplasty (PTA) ballooning of vessels alone, or of stenting in
Sapien III, Sapien 3, PARTNER III, FDA approval, expanded indication, intermediate risk patients

The Sapien 3 valve has a skirt of fabric at its base that has significantly reduced issues of paravalvular leak, which was an issue with the first generation Sapien device. 

Feature | Heart Valve Technology| August 18, 2016 | Dave Fornell
August 18, 2016 — The U.S.
Corindus Corpath, Acist Medical RXi and CVi, Fairview Southdale Hospital, Minnesota, cath lab
News | Cath Lab| August 17, 2016
Corindus Vascular Robotics Inc. and Acist Medical Systems Inc. are providing Fairview Southdale Hospital, Edina, Minn...
Overlay Init